

# Assessment event

## Description

An EVENT associated with the gathering and analysing of information concerning a PARTY.

## Properties in this Property group

- [Acute coronary syndrome related clinical event date](#)
- [Acute coronary syndrome related clinical event time](#)
- [Acute coronary syndrome symptoms onset date](#)
- [Acute coronary syndrome symptoms onset time](#)
- [Albuminuria status](#)
- [Angina episodes count](#)
- [Antibiotic susceptibility](#)
- [Apgar score](#)
- [Apgar score at 1 minute](#)
- [Apgar score at 1 minute](#)
- [Apgar score at 5 minutes](#)
- [Apgar score at 5 minutes](#)
- [Assessment of cardiac perfusion method](#)
- [Cancer diagnostic assessment date](#)
- [Cancer diagnostic assessment indicator](#)
- [Cancer diagnostic assessment type](#)
- [Cancer staging scheme source](#)
- [Cancer staging scheme source](#)
- [Cancer staging scheme source edition number](#)
- [Cancer staging scheme source edition number](#)
- [Cancer status](#)
- [Chest pain pattern](#)
- [Cholesterol level](#)
- [Coronary artery bypass graft location](#)
- [C-reactive protein level](#)
- [C-reactive protein level measured date](#)
- [C-reactive protein level measured time](#)
- [Creatine kinase isoenzyme level](#)
- [Creatine kinase-myocardial band isoenzyme level](#)
- [Creatinine serum level](#)
- [Creatinine serum level measured date](#)
- [Cytopathology result](#)
- [Degree of spread of a cancer](#)
- [Electrocardiogram date](#)
- [Electrocardiogram time](#)
- [Estimated glomerular filtration rate \(eGFR\) result](#)
- [Functional stress test ischaemic result](#)
- [Glycosylated haemoglobin level](#)
- [Help completing survey](#)
- [High-density lipoprotein cholesterol level](#)
- [Human epidermal growth factor receptor-2 test result](#)
- [Human epidermal growth factor receptor-2 test type](#)
- [Immunohistochemistry type](#)
- [Ischaemic and perfusion outcome result](#)
- [Kidney damage marker](#)
- [Killip classification](#)
- [Laterality of primary cancer](#)
- [Low-density lipoprotein cholesterol level](#)
- [Melanoma thickness](#)
- [Microalbumin level](#)
- [Mode of statistical survey completion](#)
- [Molecular pathology indicator](#)
- [Molecular pathology test date](#)
- [Molecular pathology test results](#)
- [Morphology of cancer](#)
- [Most recent stroke date](#)
- [Number of positive sentinel lymph nodes](#)

- [Number of previous caesarean sections](#)
- [Number of previous pregnancies](#)
- [Number of sentinel lymph nodes examined](#)
- [Oestrogen receptor assay result](#)
- [Outcome of treatment](#)
- [Performance status score at diagnosis](#)
- [Primary site of cancer](#)
- [Progesterone receptor assay results](#)
- [Reason for non prescription of pharmacotherapy](#)
- [Region of first recurrence as distant metastasis](#)
- [Region of first recurrence as locoregional cancer](#)
- [Sample population](#)
- [Side of ear](#)
- [Solid tumour size](#)
- [Staging basis of cancer](#)
- [Staphylococcus aureus bacteraemia clinical criteria](#)
- [Survey language](#)
- [Tissue sample collected indicator](#)
- [Triglyceride level](#)
- [Troponin level](#)
- [Type of enumeration period](#)
- [Upper limit of normal range for microalbumin](#)
- [Urine albumin level](#)
- [Urine protein level](#)
- [Ventricular ejection fraction test result](#)
- [Ventricular ejection fraction test type](#)